New improved diagnostic marker for severe blood cancer

The novel approach that will be tested in the routine diagnosis of lymphoma in the Department of Pathology is based on a new biomarker, i.e., a factor that is specific for a certain disease. The discovery is a result of research within CREATE Health, a Center for Translational Cancer Research supported by the Foundation for Strategic Research and the Wallenberg Foundation.

CREATE Health has integrated investigators from the faculties of medicine, engineering, and natural sciences together with clinical oncologists from the university hospital. The overall aim is to identify proteins and genes that can be used as biomarkers for cancer, using emerging advanced technologies. Several very promising projects are under development, but the novel diagnostic approach for MCL has advanced the furthest. Scientist Sara Ek and colleagues have by studying more than 50,000 gene fragments found those that are specifically overexpressed in this disease. She has also identified the corresponding proteins and it is one of these proteins that serves as a specific biomarker.

– In a collaboration with pathologists, we are now studying the biomarker to see if it can be used as a novel routine test for this aggressive blood cancer. In a longer perspective, knowledge about the function of these disease-specific proteins can also lead to novel therapeutic modalities for blood cancer, explains professor Carl Borrebaeck, program director for CREATE Health.

Dr. Michael Dictor, pathologist at Lund University Hospital agrees.
– The biomarker Sox11 has shown to be a very sensitive and specific marker for MCL in addition to providing new information on how the disease might arise.